Caris Life Sciences, Inc. (CAI)

Market Cap	7.76B
Revenue (ttm)	452.50M
Net Income (ttm)	-371.16M
Shares Out	277.07M
EPS (ttm)	-2.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,347,868
Open	27.00
IPO Price	21.00
Day's Range	25.56 - 29.40
52-Week Range	21.00 - 29.32
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About CAI

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company’s molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising lab...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 18, 2025
• Employees: 1,769
• Stock Exchange: NASDAQ
• Ticker Symbol: CAI
• Website: https://www.carislifesciences.com

Financial Performance

In 2024, Caris Life Sciences's revenue was $412.26 million, an increase of 34.67% compared to the previous year's $306.13 million. Losses were -$378.26 million, -18.22% less than in 2023.

Financial numbers in USD